Document:

Exhibit
10.27 

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

FORM
OF COMMON STOCK PURCHASE WARRANT

 

SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.

 

	Warrant
    No. _____	Issue
    Date: _________2021

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [              ] or any registered
assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time following the Issue Date (the “Initial Exercise Date”) and on or prior to
the close of business on ____________, 20261 (the “Termination Date”) but not thereafter,
to subscribe for and purchase from Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”),
up to 250,000 shares of Common Stock (the “Warrant Shares”). The purchase price of one share of Common Stock
under this Warrant shall be $1.00.

 

Section
1. Definitions. For the purposes hereof, in addition to the terms defined elsewhere in this Warrant, (a) capitalized terms
not otherwise defined herein shall have the meanings set forth in the Subscription Agreement entered into by the Company and the Holder
of even day herewith and (b) the following terms shall have the following meanings:

 

“Business
Day” means any day except any Saturday, any Sunday, any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Common
Stock” means the shares of common stock, $0.00001 par value per share, of the Company.

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Stock.

 

“Exercise
Period” shall have the meaning as that term is defined in Section 2(a) below.

 

 

1
Five years from the Issue Date

 

    	1 

     

    

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the New York Stock Exchange is open for business.

 

“Trading
Market” means the following markets or exchanges on which the Common Stock may be listed or quoted for trading on the date
in question: the NYSE MKT, LLC, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange.

 

“Transfer
Agent” means VStock Transfer LLC.

 

Section
2. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date (the “Exercise Period”)
by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company) of a duly executed notice of exercise
(“Notice of Exercise”) form attached hereto as Exhibit A; and, within three (3) Trading Days of the date
said Notice of Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise Price of the
shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to
the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. In the event of any dispute or discrepancy, the records of the Company shall be
controlling and determinative in the absence of manifest error.

 

b)
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $1.00.

 

 c) Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Company’s
transfer agent (the “Transfer Agent”) to the Holder by crediting the account of the Holder’s prime
broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system
if the Company is then a participant in such system and either (A) there is an effective registration statement for its initial
public offering registering the Warrants Shares, in which case the Holder will simultaneously exercise this Warrant upon the
effectiveness of such registration statement, (B) there is a registration statement permitting the resale of the Warrant Shares by
the Holder or (C) the shares are eligible for resale without volume or manner-of-sale limitations pursuant to Rule 144, and
otherwise by physical delivery of certificates to the address specified by the Holder in the Notice of Exercise within four (4)
Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant (if required) and payment of
the aggregate Exercise Price as set forth above (the “Warrant Share Delivery Date”). This Warrant shall be
deemed to have been exercised on the date the Exercise Price is received by the Company. The Warrant Shares shall be deemed to have
been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of
such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price and all
taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, have been paid.
..

 

    	2 

     

    

 

ii.
Delivery of Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant
Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by
this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right
to rescind such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be
paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by
the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of
the Holder, this Warrant when surrendered for exercise shall be accompanied by the assignment form (“Assignment
Form”) attached hereto as Exhibit B duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

vi.
Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

    	3 

     

    

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of
this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or
re-classification.

 

b)
Calculations. All calculations under this Section 4 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. For purposes of this Section 4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

 c) Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 4, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of
all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or
winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address
as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the
Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or
share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the
validity of the corporate action required to be specified in such notice. The Holder is entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice.

 

    	4 

     

    

 

Section
4. Transfer of Warrant.

 

a)
Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in
whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a
written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney
and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly
assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the
Holder or its agent or attorney. Subject to compliance with Section 5(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial
Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
5. Miscellaneous.

 

a)
No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a
shareholder of the Company prior to the exercise hereof.

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if
mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

    	5 

     

    

 

d)
Authorized Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock one
hundred (100%) of the number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under
this Warrant. In case such amount of Common Stock is insufficient at any time, the Company shall call and hold a special meeting to increase
the number of authorized shares of common stock. Management of the Company shall recommend to shareholders to vote in favor of increasing
the number of authorized shares of common stock.

 

The
Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the
purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant
Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its amended and restated certificate of incorporation, as amended, or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of
this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the laws of the State of Delaware.

 

    	6 

     

    

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will
have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be
delivered in accordance with the addresses provided by the Holder of this Warrant.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to
purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder
for the purchase price of any Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be
entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not
to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The
provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the
Holder.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the
remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a
part of this Warrant.

 

[Signature
Page Follows.]

 

    	7 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	SHUTTLE
    PHARMACEUTICALS HOLDINGS, INC.	 
	 	 	 
	By:	 	 
	Name:	Anatoly
    Dritschilo	 
	Title:	Chief
    Executive Officer	 

 

    	 

     

    

 

EXHIBIT
A

 

NOTICE
OF EXERCISE

 

TO:

 

(1)
The undersigned hereby elects to purchase _________ Warrant Shares of the Company pursuant to the terms of the attached Warrant and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as
is specified below:

 

_________________________________ 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_________________________________ 

 

_________________________________ 

 

_________________________________ 

 

(3)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.

 

	[SIGNATURE
    OF HOLDER]
	 
	Name
    of Investing Entity:
	_______________________________________________________________________________________________

    

    

	 
	Signature
    of Authorized Signatory of Investing Entity:
	__________________________________________

    

	 
	Name
    of Authorized Signatory:
	_______________________________________________________________________________________________

	 
	Title
    of Authorized Signatory:
	_______________________________________________________________________________________________

	 
	Date:
	_______________________________________________________________________________________________

 

    	 

     

    

 

EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [___] all of or [_____] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

____________________________________________whose
address is

 

 

______________________________________________________________.

 

 

 _______________________________________________________________

 

Dated:
______________, ______

 

	 	Holder’s
    Signature:	 ________________________________
	 	 	 
	 	Holder’s
    Address:	 ________________________________
	 	 	 
	 	 	________________________________

 

Signature
Guaranteed: ______________________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary
or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Exhibit
10.28 

 

CONSULTING
AGREEMENT

 

This
CONSULTING AGREEMENT (this “Agreement”) is made this 1st day of January, 2022, by and between Shuttle
Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and Steven Bayern, (the “Consultant”).

 

WHEREAS,
Consultant has experience in business development, public company and financial advisory matters; and

 

WHEREAS,
the Company desires to retain Consultant on a non-exclusive basis to render advisory services to the Company, and Consultant desires
and agrees to provide the Company with such services, in each case on the terms and conditions herein set forth.

 

NOW
THEREFORE, in consideration of the mutual covenants set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.
Engagement; Term; No Regulated Activity.

 

(a)
The Company hereby engages Consultant, and Consultant hereby accepts such engagement, to serve as a consultant to the Company and to
perform during the Term (as defined below) business advisory and consulting services, including providing advice and counsel related
to the preparation of various documents related to the Company’s planned initial public offering, introduction to qualified investors
and such other related activities and services as the Company may require from time to time (collectively, the “Services”).
The Services will be provided on a non-exclusive basis and the Company may retain other third parties to perform, and/or assist in the
performance of, the Services or any similar services during the Term (as defined below). Consultant shall report directly to the Company’s
chief executive officer, or other such officer as directed by the Company’s chief executive officer.

 

(b)
The Consultant agrees to devote such time and effort as is reasonable and adequate to render the Services contemplated by this Agreement.
However, the parties anticipate that the Consultant shall dedicate approximately 10 hours per week in performing the Services. The Consultant
represents and warrants to the Company that (i) he has the experience and ability as may be necessary to perform all of the required
Services with a high standard of quality, and (ii) all Services will be performed in a professional manner.

 

(c)
Except if terminated pursuant to Section 3 hereof, this Agreement shall have a term of twelve (12) months (the “Term”)
commencing on January 1, 2022 (the “Effective Date”). At the conclusion of the Term, this Agreement will terminate
and be of no further force and effect, unless renewed by written agreement of the Company and the Consultant.

 

2.
Consideration.

 

(a)
As consideration for the Services to be provided hereunder, during the Term, the Company will compensate the Consultant at the rate of
ten thousand dollars ($10,000.00) per month (the “Fee”).

 

(b)
In addition, the Company shall directly reimburse the Consultant for any pre-approved expenses (the “Expenses”) in
connection with the provision of the Services, provided that such Expenses must be approved in writing in advance by the Company.

 

(c)
Consultant shall be solely responsible for the payment of all federal, state and local taxes, withholdings and/or other assessments or
deductions required to be paid by any applicable law or regulation based upon Consultant’s receipt of the consideration hereunder.

 

3.
Termination. This Agreement may be terminated prior to the expiration of the Term in the manner described in this Section 3.

 

(a)
Termination upon Death. The Agreement shall terminate immediately upon Consultant’s death.

 

    	 

     

    

 

(b)
Termination upon Disability. The Company shall have the right to terminate this Agreement during the continuance of any Disability
of the Consultant, as hereafter defined, upon ten (10) days’ prior written notice to the Consultant during the continuance of the
Disability.

 

(c)
Termination by the Company without Good Cause. The Company shall have the right to terminate the Agreement for any reason, with
or without Good Cause (as hereinafter defined), upon thirty (30) days’ prior written notice to the Consultant.

 

(d)
Termination by the Company for Good Cause. The Company shall have the right to immediately terminate the Agreement for Good Cause,
as hereinafter defined, by written notice to the Consultant specifying the particulars of the circumstances forming the basis for such
Good Cause.

 

(e)
Termination Date. The “Termination Date” is the date as of which the Agreement terminates. Any notice of termination
given pursuant to the provisions of this Agreement shall specify the Termination Date.

 

(f)
Certain Definitions. For purposes of this Agreement, the following terms shall have the following meanings:

 

(i)
“Disability,” as used herein, shall mean an inability by the Consultant to perform a substantial portion of the Services
hereunder by reason of physical or mental incapacity or disability for a total of thirty (30) days or more in any consecutive period
of sixty (60) days, as determined by the Company, in its good faith judgment.

 

(ii)
“Disparage,” as used herein, shall mean, without limitation, comments or statements to the press, comments or statements
posted on any internet site, concerning any of the Company’s or its affiliates’ officers, directors or employees, or any
person with whom the Company or any affiliate has a business relationship, which are designed to, or would reasonably be expected to,
adversely affect in any manner the conduct of any of the Company’s or any of such affiliates’ business or the business or
personal reputations of the Company, its affiliates, or any of the Company’s or its affiliates’ officers, directors, employees
or shareholders.

 

(iii)
“Good Cause,” as used herein, shall mean (A) the commission of a felony, or a crime involving moral turpitude, or
the commission of any other act or omission involving dishonesty, disloyalty, or fraud with respect to the Company; (B) conduct tending
to bring the Company or any of its affiliates into public disgrace or disrepute; (C) substantial and repeated failure to perform the
Services; (D) negligence or willful misconduct with respect to the Company or any of its affiliates; (E) the Consultant Disparages (or
induces or encourages others to Disparage) the Company; or (F) any material misrepresentation made by the Consultant under this Agreement.

 

(g)
Obligations of Company on Termination. Notwithstanding anything in this Agreement to the contrary, the Company’s only obligations
to the Consultant upon termination of the Agreement shall be to pay Consultant any portion of the Fee and/or pre-approved unreimbursed
expenses accrued but unpaid as of the Terminationa Date.

 

4.
Independent Contractor. The relationship of Consultant with the Company hereunder is that of an independent contractor and consultant
and in no event shall Consultant be considered an employee agent, partner, co-venturer or controlling person of the Company. In connection
with the provision of the Services hereunder, the Consultant will not make any binding representations about the Company, nor shall it
act as the Company’s agent, nor shall it have any right or authority whatsoever to propose or accept, in the name and on behalf
of the Company, any representation, undertaking, guarantee, promise, agreement, contract or any other kind of an obligation.

 

    	2

     

    

 

5.
Covenants of the Consultant.

 

(a)
Confidentiality.

 

(i)
The Consultant recognizes that the Consultant’s position with the Company is one of trust and confidence. The Consultant acknowledges
that the Company has devoted substantial time, effort and resources to developing the Company’s business and that, during the Term,
the Consultant will necessarily become acquainted with confidential information relating to the Company’s business and trade secrets,
processes, methods of operation and other information, which the Company regards as confidential in nature (collectively, “Confidential
Information”). The Consultant acknowledges and agrees that the Confidential Information is of incalculable value to the
Company and that the Company would suffer irreparable damage if any of the Confidential Information was improperly disclosed.

 

(ii)
The Consultant recognizes that because of Consultant’s access to the Company’s Confidential Information, Consultant would
be in a unique position to divert business from the Company and to commit irreparable damage to the Company were Consultant to be allowed
to divulge any of the Confidential Information.

 

(iii)
The Consultant covenants and agrees that the Consultant will not, at any time during the term, or after the expiration or sooner termination
of the Agreement, regardless of whether termination is initiated by the Consultant or the Company, reveal, divulge, or make known to
any person, firm or corporation, any Confidential Information made known to the Consultant or of which the Consultant has become aware,
regardless of whether developed, prepared, devised or otherwise created in whole or in part by the efforts of the Consultant, except
and to the extent that such disclosure is necessary to carry out the Services. The Consultant further covenants and agrees that the Consultant
shall retain all Confidential Information in trust for the sole benefit of the Company, and will not divulge, deliver or show any Confidential
Information to any unauthorized persons, and the Consultant will not make use of such Confidential Information in an independent business,
whether related to the business of the Company or otherwise, without the Company’s express written cosent; provided, however, that
the Consultant has no obligation, express or implied, to refrain from using or disclosing to others any such knowledge or information
which is or hereafter shall become available to the public by means other than through disclosure by the Consultant.

 

(iv)
The Consultant agrees that, upon termination of the Agreement, for any reason whatsoever, or for no reason, and at any time, the Consultant
shall return to the Company all papers, documents and other property of the Company placed in the Consultant’s custody or which
was obtained by the Consultant during the Term as such documents or property relate to Confidential Information, and the Consultant will
not retain copies of any such papers, documents or other property for any purpose whatsoever.

 

(b)
Non-Solicitation of Employees and Independent Contractors. Consultant will not, during the Term, and for one (1) year after the
expiration or sooner termination of this Agreement, regardless of whether termination is initiated by either Consultant or the Company,
for any reason, directly or indirectly (i) induce or attempt to induce any employee or an independent contractor of the Company to leave
the employ or contracting relationship with the Company, or in any way interfere with the relationship between the Company and any employee
or an independent contractor thereof, (ii) solicit for employment or as an independent contractor any person who was an employee or full-time
independent contractor of the Company at any time during the Term, or (iii) induce or attempt to induce any customer, supplier or other
business relation of the Company to cease doing business with the Company or in any way interfere with the relationship between any such
customer, supplier or other business relation and the Company.

 

    	3

     

    

 

(c)
Work Product. The Consultant agrees that all innovations, inventions, improvements, developments, methods, designs, analyses,
drawings, reports, and all similar or related information which relate to the Company’s business, or any business which the Company
has taken significant action to pursue, and which are conceived, developed or made by the Consultant during the Term (any of the foregoing
hereinafter referred to as “Work Product”), belong to the Company. The Consultant will promptly disclose all such
Work Product to the board of directors of the Company and perform all actions reasonably requested by the board (whether during Term
or after the Termination Date) to establish and confirm such ownership (including, without limitation, assignments, consents, powers
of attorney and other instruments).

 

(d)
No Conflict. The Consultant represents that he has all the necessary right, power and authority to enter into this Agreement,
to serve as a Consultant to the Company, to grant the rights granted to the Company by him hereunder, and to fulfill all of his obligations
under, and all of the other terms of, this Agreement. The Consultant represents and warrants to the Company that the Consultant is not
a party to or bound by any employment agreement, consulting agreement, noncompete agreement or confidentiality agreement with any other
person or entity or any other agreement, which would prevent or limit his ability to enter into this Agreement or perform his obligations
hereunder.

 

(e)
No Broker-Dealer or other Remuneration. The Consultant represents and warrants that, in providing the Services, Consultant has
not and will not engage in any activity that will result in the Consultant being deemed to be a broker or dealer as defined under Section
3(a)(4) or Section 3(a)(5) of the Securities Exchange Act of 1934, as amended. The Consultant will not receive any fees, commissions
or other remuneration in connection with any financingor offering conducted by the Company, whether from investment bankers, underwriters,
placement agents or other entities. The Consultant understands, agrees and acknowledges that the Company is expressly relying on the
representations and warranties set forth herein and agrees to indemnify and hold harmless the Company and its affiliates, subsidiaries,
members, shareholders, partners, employees, agents and representatives (each, a “Company Entity”) from any claims, damages,
liabilities, obligations, penalties, enforcement actions or other losses (each, a “Claim”) that relate to or arise from (i)
the breach by the Consultant of the representations, warranties, covenants and agreements contained in this paragraph, or (ii) any Claim
that relates to or arises from any other consultant, advisor or other party alleging that it is entitled to a fee or any other amount
or compensation for any service of Consultant contemplated by this Agreement or that any such person or entity is entitled to a portion
of any such fee, amount or compensation. The provisions of this paragraph shall survive the termination of this Agreement and the performance
of Services and transactions contemplated herein.

 

    	4

     

    

 

(f)
Enforcement.

 

(i)
The Consultant acknowledges that the Company will suffer substantial and irreparable damages not readily ascertainable or compensable
in the event of the breach of any of the Consultant’s obligations under Sections 5(a) through 5(e) hereof. The Consultant therefore
agrees that the provisions of Sections 5(a) through 5(e) shall be construed as an agreement independent of the other provisions of this
Agreement and any other agreement, and that the Company, in addition to any other remedies (including damages) provided by law, shall
have the right and remedy to have such provisions specifically enforced by any court having equity jurisdiction thereof. Accordingly,
in addition to all of the Company’s rights and remedies under this Agreement, including but not limited to, the right to the recovery
of monetary damages from the Consultant, the Company shall be entitled, and the Consultant hereby consents, to the issuance by any court
of competent jurisdiction of temporary, preliminary and permanent injunctions, without bond, enjoining any such breach or threatened
breach of this Agreement by the Consultant. The Consultant’s sole remedy in the event of any injunction or order shall be dissolution
thereof, if warranted, upon duly held hearing in a court of competent jurisdiction. The Consultant hereby waives all claims for damages
for wrongful issuance of any such injunction. The rights and remedies set forth in this Section 5(e) shall be in addition to, and not
in lieu of, any other rights and remedies available to the Company under law or equity.

 

(ii)
If at any time any of the provisions of this Section 5 shall be determined to be invalid or unenforceable, by reason of being vague or
unreasonable as to area, duration or scope of activity, this Section 5 shall be considered divisible and shall become and be immediately
amended only to such area, duration and scope of activity as shall be determined to be reasonable and enforceable by the court or other
body having jurisdiction over the matter, and the Consultant agrees that this Section 5, as so amended, shall be valid and binding as
though any invalid or unenforceable provision had not been included herein.

 

6.
No Assignment. Consultant shall not assign any of its rights or obligations under this Agreement without the prior written consent
of the Company.

 

7.
Indemnification. The Consultant agrees to indemnify, defend and hold harmless the Company and its subsidiaries and its and their
respective officers, directors, employees, agents and advisors (“Company Indemnified Persons”) from and against any
and all losses which any of them may incur, based on or arising from actual or alleged breach of this Agreement by the Consultant, gross
negligence, willful misconduct, or infringement of patent rights, misappropriation of trade secrets, or breach of confidentiality by
the Consultant; provided, however, that, the Consultant may not settle or agree to settle any such loss without the Company’s prior
written consent.

 

8.
Governing Law; Venue. This Agreement shall be governed by the laws of the State of Maryland, without regard to the conflicts of
laws principles thereof. Each of Consultant and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating
to this Agreement and/or the transactions contemplated hereby shall be instituted only in the federal or state courts of the State of
Maryland, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably
consents to the jurisdiction of the in the Maryland District Court, located in Montgomery County, or the United States District Court
for the District of Maryland, in any such suit, action or proceeding. Each of Consultant and the Company further agrees to accept and
acknowledge service of any and all process which may be served in any such suit, action or proceeding in the Maryland District Court,
County of Montgomery, or in the United States District Court for the District of Maryland, and agrees that service of process pursuant
to the laws of the State of Maryland shall be deemed in every respect effective service of process upon Consultant or the Company, as
the case may be.

 

9.
Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal
delivery, whether delivered by hand or through email (so long as receipt of such delivery is confirmed), or five days after deposit in
the United States Post Office, by registered or certified mail, postage prepaid, or upon confirmation of delivery by nationwide overnight
courier, addressed to the other party at the address shown beneath its or her signature below, or at such other address or addresses
as either party shall designate to the other in accordance with this Section 9.

 

10.
Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject
matter hereof and supersedes any and all prior or contemporaneous agreements or understandings between the parties, whether written or
oral. In addition, any amendment or modification of this Agreement will only be effective or binding unless reduced to writing and executed
by both parties hereto.

 

11.
Execution and Counterparts. This Agreement may be executed in two counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

    	5

     

    

 

IN
WITNESS WHEREOF, the parties hereto have signed this Consulting Agreement on the date first above written.

 

 

	CONSULTANT	 	SHUTTLE
PHARMACEUTIALS HOLDINGS, INC.

	 	 	 	 
	 	 	By:	 
	Steve
    Bayern	 	 	Anatoly
    Dritschilo, CEO
	 	 	 	 
	Address:
    1310 Gulf Blvd Apt. 15A	 	 	Address:
    1 Research Court, Suite 450
	Clearwater,
    FL 33676	 	 	Rockville,
    MD 20850

 

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]